Type 2 diabetes (T2D) affects over 400 million people globally, and a significant portion struggle to maintain adequate blood glucose control despite available treatments. Current therapies often focus on managing downstream effects rather than addressing the underlying metabolic dysfunction, potentially leading to disease progression and increased healthcare costs.

Endogenex is developing the ReCET™ System, an investigational device designed to reset metabolic signaling in the duodenum using controlled, non-thermal pulsed electric fields delivered endoscopically. The ReCET System aims to restore the natural signaling process of the duodenum, helping the body better control blood glucose levels and potentially slow the progression of type 2 diabetes. The technology is based on the principle of eliminating poorly functioning signaling cells in the duodenum to reset the metabolic operating system. The ReCET system is currently under evaluation in clinical studies in the United States and Australia.

Endoscopic delivery of controlled, non-thermal pulsed electric fields to the duodenum

Designed to reset metabolic signaling and restore natural signaling processes

Aims to improve blood glucose control and slow the progression of type 2 diabetes

Utilizes a novel approach to eliminate poorly functioning signaling cells

Investigational device under evaluation in pivotal clinical studies

The primary audience includes clinical providers, such as endocrinologists and gastroenterologists, interested in novel therapeutic approaches for managing type 2 diabetes, as well as patients with T2D seeking alternative treatment options.